
During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
New indications: Leukotriene blocker approved for treatment of seasonal allergic rhinitis






